scholarly journals Global, Regional, and National Burden of Urinary Tract Infections from 1990-2019: an Analysis of the Global Burden of Disease Study 2019

2021 ◽  
Author(s):  
Zhilin Zeng ◽  
Juan Zhan ◽  
Kaimin Zhang ◽  
Huilong Chen ◽  
Sheng Cheng
Keyword(s):  
Incidence Rate ◽  
National Level ◽  
Disability Adjusted Life Years ◽  
Development Status ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Study Results ◽  
National Burden ◽  
Disease Study ◽  
Tract Infections

Abstract Objective We aimed to estimate the burden of UTIs by age, sex, and socioeconomic status in 204 countries and territories from 1990–2019. Method We used data from GBD 2019 to analyse the incidence, mortality, and disability-adjusted life-years (DALYs) due to UTIs at the global, regional, and national levels. Estimates are presented as numbers and age-standardised or age-specific rates per 100000 population, with 95% uncertainty intervals (UIs). We further explored the associations between the incidence, mortality, DALYs, and socio-demographic index (SDI) as a proxy for the development status of regions and countries. Results In 2019, more than 404.6 million (95% UI 359.4-446.5) individuals had UTIs globally and nearly 236 786 people (198 433 − 259 034) died of UTIs, contributing to 5.2 million (4.5–5.7) DALYs. The age-standardised incidence rate increased from 4 715.0 (4 174.2-5 220.6) per 100 000 population in 1990 to 5 229.3 (4 645.3-5 771.2) per 100 000 population in 2019. At the GBD regional level, the highest age-standardised incidence rate in 2019 occurred in Tropical Latin America (13 852.9 [12 135.6–15 480.3] per 100 000 population). At the national level, Ecuador had the highest age-standardised incidence rate (15 511.3 [13 685.0–17 375.6] per 100 000 population). The age-standardised death rates were highest in Barbados (19.5 [13.7–23.5] per 100 000 population). In addition, age-standardised incidence, death, and DALY rates generally increased across the SDI. Conclusions Our study results suggest a globally rising trend of UTI burden between 1990 and 2019. The results of this study could be useful in policy-making, priority setting, and resource allocation in UTI prevention and treatment.

Global, regional, and national burden of other musculoskeletal disorders 1990–2017: results from the Global Burden of Disease Study 2017

Rheumatology ◽  
2020 ◽  
Author(s):  
Saeid Safiri ◽  
Ali Asghar Kolahi ◽  
Marita Cross ◽  
Kristin Carson-Chahhoud ◽  
Amir Almasi-Hashiani ◽  
...  
Keyword(s):  
Burden Of Disease ◽  
National Level ◽  
Point Prevalence ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Prevalence Estimates ◽  
National Burden ◽  
Disease Study

Abstract Objectives To describe the level and trends of point prevalence, deaths and disability-adjusted life years (DALYs) for other musculoskeletal (MSK) disorders, i.e. those not covered by specific estimates generated for RA, OA, low back pain, neck pain and gout, from 1990 to 2017 by age, sex and sociodemographic index. Methods Publicly available modelled estimates from the Global Burden of Disease (GBD) 2017 study were extracted and reported as counts and age-standardized rates per 100 000 population for 195 countries and territories between 1990 and 2017. Results Globally, the age-standardized point prevalence estimates and deaths rates of other MSK disorders in 2017 were 4151.1 and 1.0 per 100 000. This was an increase of 3.4% and 7.2%, respectively. The age-standardized DALY rate in 2017 was 380.2, an increase of 3.4%. The point prevalence estimate was higher among females and increased with age. This peaked in the 65–69 year age group for both females and males in 2017, followed by a decreasing trend for both sexes. At the national level, the highest age-standardized point prevalence estimates in 2017 were seen in Bangladesh, India and Nepal. The largest increases in age-standardized point prevalence estimates were observed in Romania, Croatia and Armenia. Conclusion The burden of other MSK disorders is proven to be substantial and increasing worldwide, with a notable intercountry variation. Data pertaining to specific diseases within this overarching category are required for future GBD MSK estimates. This would enable policymakers to better allocate resources and provide interventions appropriately.

scholarly journals Burden of multiple sclerosis in Iran from 1990 to 2017

BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Nima Fattahi ◽  
Sahar Saeedi Moghaddam ◽  
Farnam Mohebi ◽  
Negar Rezaei ◽  
Masoud Masinaei ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Incidence Rate ◽  
National Level ◽  
Uncertainty Interval ◽  
Policy Makers ◽  
Disability Adjusted Life ◽  
Life Years ◽  
The Central Nervous System ◽  
Disease Study ◽  
Standardized Mortality Rate

Abstract Background Multiple Sclerosis (MS) is a burdensome, chronic and autoimmune disease of the central nervous system. We aimed to report the incidence, prevalence, mortality, and Disability Adjusted Life Years (DALYs) of MS in Iran at a national level for different age and sex groups over a period of 28 years (1990–2017). Methods Data were extracted from the Global Burden of Disease study (GBD) from 1990 to 2017, published by the Institute for Health Metrics and Evaluation. The incidence of DALYs and prevalence of MS were estimated to report the burden of MS based on sex and age in Iran from 1990 to 2017. Results At the national level, the Age-Standardized Incidence Rate (ASIR), Age-Standardized Prevalence Rate (ASPR), Age-Standardized DALYs Rate (ASDR) and the Age-Standardized Mortality Rate (ASMR) in Iran in 2017 were 2.4 (95% Uncertainty Interval [UI]: 2.1 to 2.7), 69.5 (62.1 to 77.8), 29.1 (23.6 to 34.7), and 0.4 (0.3 to 0.4) per 100,000 population, respectively. During the period of 1990 to 2017, all measures increased, and were higher among females. The incidence rate began upward trend at the age of 20 and attained its highest level at the age of 25. Conclusion In Iran, all of the age-standardized MS rates have been increasing during the 28 years from 1990 to 2017. Our findings can help policy makers and health planners to design and communicate their plans and to have a better resource allocation, depending on the incidence and prevalence of the growing numbers of MS patients in Iran.

scholarly journals Global, regional and national burden of gout, 1990–2017: a systematic analysis of the Global Burden of Disease Study

Rheumatology ◽  
2019 ◽  
Vol 59 (7) ◽  
pp. 1529-1538 ◽  
Author(s):  
Yang Xia ◽  
Qijun Wu ◽  
Hanyuan Wang ◽  
Shuang Zhang ◽  
Yuting Jiang ◽  
...  
Keyword(s):  
Burden Of Disease ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Disability Adjusted Life Years ◽  
Annual Percent Change ◽  
Percent Change ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Study Results ◽  
Disease Study

Abstract Objectives The burden of gout has been increasing globally. However, little is known about the global, regional and national distribution and time trend of this disease. We present a comprehensive analysis of the Global Burden of Disease Study 2017 on gout burden estimates for 195 countries or territories between 1990 and 2017. Methods Age-standardized prevalence and disability-adjusted life-years of gout were reported between 1990 and 2017 in 195 countries and territories, and associations between these estimates and sociodemographic index (SDI) were further explored. Total and annual percent change between 1990 and 2017 were calculated to quantify the time trends of gout burden. Results Age-standardized prevalence rates (95% uncertainty interval) per 100 000 persons were 790.90 (706.10–881.90) and 253.49 (225.69–284.02) in 2017 in males and females, respectively. The annual percent change in age-standardized prevalence (males, 0.22%; females, 0.38%) and disability-adjusted life-years (males, 0.21%; females, 0.38%) of gout increased every year from 1990 to 2017, globally. The highest increase was detected in high-SDI countries, especially in high-income North America. A non-linear association was observed between burden of gout and SDI, with the lowest estimates of gout burden when SDI value was about 0.6. High BMI was the leading risk factor for the burden of gout. Conclusion These study results suggest a globally rising trajectory of gout burden between 1990 and 2017. More effective interventions, such as detailed and intensive dietary managements and other prevention strategies for reducing obesity, should be carried out to reverse this trend, especially in females and high-SDI countries.

scholarly journals Burden of breast cancer in Serbia 2007-2017

2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
J Todorovic ◽  
M Santric-Milicevic ◽  
Z Stamenkovic ◽  
V Bjegovic-Mikanovic ◽  
Z Terzic-Supic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Incidence Rate ◽  
Breast Cancer Incidence ◽  
Disability Adjusted Life Years ◽  
The Past ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Total Cancer ◽  
Disease Study ◽  
Years Lived With Disability

Abstract Background Breast cancer is the third highest incidence of cancer globally. It is the leading cause of cancer-associated mortality among females in the world. In Serbia, the incidence rate of breast cancer in 2015 was 61.0/100000 and breast cancer attributed to 18.9% of total cancer mortality among females. The aim of this study was to examine the incidence rate, years lived with disability (YLD) and disability-adjusted life-years (DALY) in Serbia in the ten-year period, from 2007 to 2017. Methods We analyzed data from the global burden of disease study (GBD) 2017. The data for the breast cancer incidence, prevalence, YLD, DALY counts and DALY rates per 100,000 were used for analyses. Results The prevalence of breast cancer in Serbia (in thousands) in 2017 was 44.6 (95% CI: 39.9-50.6), the incidence (in thousands) was 5.6 (95% CI: 5.0-6.4), YLD (in thousands) in 2017 was 3.5 (95% CI: 2.5-4.9). In the period between 2007 and 2017, YLD counts increased by 11.7%, while the age-standardized rates increased by 5.8%. Total all age DALY counts for both sexes were 51.8 (95% CI: 49- 55.3) in 2007 and 51.5 (95% CI: 45.7-58.3) in 2017. Age-standardized DALY rates per 100,000 decreased from 388.8 (95% CI: 368.3-415.7) in 2007 to 366.3 (95% CI: 323.8-415.4) in 2017. Conclusions The data from the GBD study show that the total YLD counts in Serbia increased by more than 10% in the past decade. However, the total DALY counts did not change significantly and the age-standardized DALY rate per 100,000 decreased in the period between 2007 and 2017. Key messages The total years-lived with disability as a consequence of the breast cancer increased for 10% in Serbia between 2007 and 2017. The decrease in age-standardized DALYs may reflect aging and depopulation effects in Serbia.

The national burden of cerebrovascular diseases in Spain: A population-based study using disability-adjusted life years

2015 ◽  
Vol 144 (8) ◽  
pp. 353-359 ◽  
Author(s):  
Ferrán Catalá-López ◽  
Nerea Fernández de Larrea-Baz ◽  
Consuelo Morant-Ginestar ◽  
Elena Álvarez-Martín ◽  
Jaime Díaz-Guzmán ◽  
...  
Keyword(s):  
Population Based ◽  
Cerebrovascular Diseases ◽  
Disability Adjusted Life Years ◽  
Population Based Study ◽  
Disability Adjusted Life ◽  
Life Years ◽  
National Burden

scholarly journals The global, regional, and national burden of acute pancreatitis in 204 countries and territories, 1990–2019

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Chang-li Li ◽  
Meng Jiang ◽  
Chun-qiu Pan ◽  
Jian Li ◽  
Li-gang Xu
Keyword(s):  
Acute Pancreatitis ◽  
Gastrointestinal Disease ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Global Age ◽  
National Burden ◽  
Geographically Targeted ◽  
Disease Study ◽  
Incident Cases ◽  
Standardized Mortality Rate

Abstract Background Acute pancreatitis is a common and potentially lethal gastrointestinal disease, but literatures for the disease burden are scarce for many countries. Understanding the current burden of acute pancreatitis and the different trends across various countries is essential for formulating effective preventive intervenes. We aimed to report the incidence, mortality, and disability-adjusted life-years (DALYs) caused by acute pancreatitis in 204 countries and territories between 1990 and 2019. Methods Estimates from the Global Burden of Disease Study 2019 (GBD 2019) were used to analyze the epidemiology of acute pancreatitis at the global, regional, and national levels. We also reported the correlation between development status and acute pancreatitis’ age-standardized DALY rates, and calculated DALYs attributable to alcohol etiology that had evidence of causation with acute pancreatitis. All of the estimates were shown as counts and age-standardized rates per 100,000 person-years. Results There were 2,814,972.3 (95% UI 2,414,361.3–3,293,591.8) incident cases of acute pancreatitis occurred in 2019 globally; 1,273,955.2 (1,098,304.6–1,478,594.1) in women and 1,541,017.1 (1,307,264.4–1,814,454.3) in men. The global age-standardized incidence rate declined from 37.9/100,000 to 34.8/100,000 during 1990–2019, an annual decrease of 8.4% (5.9–10.4%). In 2019, there were 115,053.2 (104,304.4–128,173.4) deaths and 3,641,105.7 (3,282,952.5–4,026,948.1) DALYs due to acute pancreatitis. The global age-standardized mortality rate decreased by 17.2% (6.6–27.1%) annually from 1.7/100,000 in 1990 to 1.4/100,000 in 2019; over the same period, the age-standardized DALY rate declined by 17.6% (7.8–27.0%) annually. There were substantial differences in the incidence, mortality and DALYs across regions. Alcohol etiology attributed to a sizable fraction of acute pancreatitis-related deaths, especially in the high and high-middle SDI regions. Conclusion Substantial variation existed in the burden of acute pancreatitis worldwide, and the overall burden remains high with aging population. Geographically targeted considerations are needed to tailor future intervenes to relieve the burden of acute pancreatitis in specific countries, especially for Eastern Europe.

Sign in / Sign up

Export Citation Format

Share Document